Articles On Rhythm Biosciences (ASX:RHY)

The Rhythm Biosciences Ltd (ASX: RHY) share price is on a rollercoaster ride today following the company’s latest release. It surged 11.57% at market open today before falling to $1.18 — 2.5% lower than its previous close. However, the me...

Race Oncology is set to commence Phase 1 study of Zantrene after being given governance approval Rhythm Biosciences has filed blood test ColoSTAT with the TGA Proteomics gets $400k government funding Race Oncology (ASX:RAC) has just recei...

ASX to rise this morning despite sharp falls on Wall Street US CPI is persistently high, but may have reached a peak Bitcoin falls below US$30k Sticky US inflation drags Wall Street lower Aussie shares are set to open marginally higher th...

Transformative cancer diagnostics technology company Rhythm Biosciences (RHY) closes its final ColoSTAT clinical trial site The closure of all the clinical trial sites signifies the finality of clinical trial operations, marking another mi...

Today, Stockhead is having a bit of a moment. We’re just a couple of months shy of being a part of ASX small caps investors’ daily lives for five years. It’s hard to believe that since kicking off with all you need to know about Analytica’s...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Prescient Thereapeutics gives hope with its personalised Car-T cell therapy Imugene working to activate the immune systems of cancer suffers to fight disease Rhythm Bioscience revolutionising the detection of bowel cancer According to th...

Elio D’Amato, Spotee Connect BUY RECOMMENDATIONS Rhythm Biosciences (RHY)   The ColoSTAT screening test achieved a high sensitivity rate in detecting colorectal cancer. It’s estimated the test is 35 per cent more accurate than current globa...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

It’s been an emotional ride for fans of the ASX200 (XJO) which, alongside the Emerging Companies (XEC) index, (down 0.6%) gave up its early gains in a topsy-turvy Monday session. Just after the close, the XJO was weepingly flat – well, up 0...

S&P/ASX 200 healthcare index modestly up 0.16% for week Gut health company Microba falls on IPO Rhythm Biosciences bowel cancer blood screening test milestone Have a habit of forgetting where you put your keys or mobile phone? You ma...

ASX Emerging Companies (XEC) Index is about 1.25% higher ahead of the close on Monday Iron ore shakes $US160, Aussie rattles US75¢ Major movers today: Top End Energy (ASX:TEE), Golden Deeps (ASX:GED), Sayona Mining (ASX:SYA)   The ASX Eme...

Rhythm Biosciences (RHY) “successfully achieves” the end points for its clinical trial (study seven) of its ColoSTAT blood test ColoSTAT is a simple, low-cost blood test for detecting colorectal cancer that has the potential to ultimately...

Rhythm Biosciences releases positive results of ColoSTAT MedAdvisor’s acquisition Adheris exceeds revenue target In a major development today, Rhythm Biosciences (ASX:RHY) was up 15% after announcing that its blood test product ColoSTAT e...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Rhythm Biosciences (RHY) has achieved ISO certification for its colorectal cancer-detecting blood test for the fourth year running The company says the milestone is critically important as part of regulatory approvals for its commercial an...

Key points The Rhythm Biosciences share price finished the day up by more than 8% after earlier jumping by 19% The diagnostics company released its latest quarterly results today Its colorectal cancer detection product, ColoSTAT, is set t...

Ouch. The ASX has closed the third trading day of the year with a melt down of 2.74%. The Australian sharemarket has suffered its biggest one-day fall in 16 months, since 4 September 2020. The selling has been widespread with every sector...

Rhythm Biosciences (RHY) gains approval for its blood test ColoSTAT to be marketed and sold in the United Kingdom ColoSTAT is a simple, low-cost blood test for detecting colorectal cancer which removes the unpleasantness often associated w...

The Rhythm Biosciences Ltd (ASX: RHY) share price is surging on Thursday afternoon trade. This comes after the company announced two positive updates regarding its ColoSTAT product and a share placement. At the time of writing, the medical...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The Rhythm Biosciences Ltd (ASX: RHY) share price is on the move today. This comes after the company revealed its intentions to expand ColoSTAT into new cancer markets. At the time of writing, the medical device company’s shares are tradin...

Rhythm Biosciences (RHY) identifies five new cancer detection markets to expand its platform technology The new markets for breast, cervical, lung, gastric and pancreatic cancer will be explored as part of a research and development progra...

The ASX 200 Health Index (XHJ) is trading higher by 0.27% at the time of writing, compared to the broader index which is down by 0.40%. Fertility company Virtus Health (ASX:VRT) is being pursued by a takeover offer from BGH Capital. BGH, wh...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Rhythm Biosciences (RHY) restructures board and management team, effective immediately Current Chair Otto Buttula has transitioned to the Executive Chair role and current CEO Glenn Gilbert has been appointed Managing Director The company s...

Cancer diagnostic technology company Rhythm Biosciences (RHY) achieves CE Mark certification for ColoSTAT This certification indicates Rhythm’s products comply with the EU’s IVD Directives, which are a series of legislative requirement to...

Cancer diagnostics company Rhythm Biosciences Ltd (ASX:RHY) got a regulatory boost this morning, with news that CE Mark approval is now complete for its ColoSTAT blood test platform in the European market. Shares in the ~$350m company conti...

The Rhythm Biosciences Ltd (ASX: RHY) share price is on fire on Tuesday morning. At the time of writing, the cancer diagnostics technology company’s shares are up 15% to $1.90. This means the Rhythm Biosciences share price is now up an imp...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

The share market looked set to open little changed following a mixed close on Wall Street as rising interest rates boosted lenders and depressed growth stocks. ASX futures inched up a point or 0.01 per cent as the Dow led for a second ni...

Aussie shares looked set to start the week in retreat following a risk-off session in the US after pandemic restrictions tightened in parts of Europe. US stocks ended mixed on Friday as traders rotated out of cyclical sectors into lockdo...

In October, the Chinese government released its intellectual proprietary (IP) patents strategy paper, listing its main goals for the next five years. Part of that plan is to double the foreign “high value” patents from the current 40,000 to...

It was a mixed bag of results for ASX healthcare shares as we walked through October, as some names came in red hot, whilst others missed the mark completely. After a sharp downturn in late September, where it lost around 7% in just one w...

Shares in medical diagnostics company Rhythm Biosciences Ltd (ASX: RHY) are edging higher in afternoon trade today. At the time of writing, Rhythm Biosciences shares are changing hands at $1.59 apiece, which is an almost 3% gain from yest...

The Rhythm Biosciences Ltd (ASX: RHY) share price is lifting in early trade today as the medical technology company released an investor presentation. At the time of writing, Rhythm Biosciences shares are changing hands at $1.50 each, sig...

The ASX 200 Health Index (XHJ) is up by 0.80% at the time of writing, compared to the broader index which is higher by 0.7%. Notices from both the Australian and European Patent Offices have been received by Noxopharm (ASX:NOX), relating to...

The Rhythm Biosciences Ltd (ASX: RHY) share price is on the move during late morning trade on Thursday. This comes after the medical device company provided an update in regards to its colorectal cancer test kit product, ColoSTAT. At the...

The ASX 200 health stocks index (XHJ) is falling by 0.55% at the time of writing, compared to the broader ASX 200 index which fell by 0.50%. Fibrotic and inflammatory diseases-focused biotech, Pharmaxis (ASX:PXS), has just announced further...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week The Healthc...

Rhythm Biosciences (ASX:RHY) has announced the appointment of a new chair with the resignation of incumbent Shane Tanner.

The Rhythm Biosciences Ltd (ASX: RHY) share price was a very strong performer on Wednesday. The predictive diagnostics company’s shares ended the day 12% higher at $1.32. This means the Rhythm Biosciences share price is now up 550% over th...

Highlights CIMIC Group shares dropped even after one of its companies secured a contract extension. Mineral sands player Heavy Minerals made a weak debut on the ASX today. Hotel Property Investments and Vulcan Energy shares are under...

The Rhythm Biosciences Ltd (ASX: RHY) share price is pushing higher on Tuesday. In afternoon trade, the predictive diagnostics company’s shares are up 8.5% to $1.14. Why is the Rhythm Biosciences share price racing higher? Investors have b...

Highlights The ASX 200 was down 12% by 7,416, paring early losses. Six of the 11 indices were trading in the red, while energy gained the most. Energy companies Beach Energy, Woodside, AGL, Santos and Oil Search topped the gainers’ ch...

Just under two years since Otto Buttula became chairman of Rhythm Biosciences (ASX:RHY), it has gained over 500% since – and the boss of the high flying biotech just chipped more in. Buttula, who in the past has headed financial services fi...

The Rhythm Biosciences Ltd (ASX: RHY) share price is charging higher in afternoon trade, up 7% to $1.21 per share. Below we take a look at what’s driving investor interest in the ASX medical diagnostics technology company. What did Rhythm...